Scinai Immunotherapeutics (NASDAQ:SCNI) Stock to Reverse Split on Friday, August 21st

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI)’s stock is going to reverse split on the morning of Friday, August 21st. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, August 20th.

Scinai Immunotherapeutics Stock Performance

NASDAQ:SCNI opened at $0.25 on Thursday. The firm’s 50-day moving average is $0.28 and its 200-day moving average is $0.54. Scinai Immunotherapeutics has a 52-week low of $0.21 and a 52-week high of $1.97. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.35 and a current ratio of 1.35. The company has a market cap of $1.28 million, a price-to-earnings ratio of -0.23 and a beta of 2.08.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Scinai Immunotherapeutics presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC boosted its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the period. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 58.41% of the company’s stock.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.